A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 Mar 2015 Biomarkers information updated
- 06 Jun 2012 Actual patient number is 19 according to ClinicalTrials.gov.
- 06 Jun 2012 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.